Test Price
2,800 AED✅ Home Collection Available
HBG2 Gene Hereditary Persistence of Fetal Hemoglobin (HPFH) Genetic Test in UAE – 2800 AED – DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity – ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139)
- Accuracy Guarantee: 99.9% diagnostic sensitivity via NGS full-gene sequencing with ISO-accredited processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM.
- Clinical Guidance: Telephonic post-test interpretation with genetic counseling support included.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
- Turnaround: Comprehensive report in 3 to 4 weeks from sample receipt.
Test Overview & Methodology
The HBG2 HPFH NGS test analyzes the full coding region of the gamma-globin gene (HBG2) to detect single nucleotide variants, small insertions/deletions, and large rearrangements responsible for hereditary persistence of fetal hemoglobin. This next-generation sequencing approach replaces older targeted methods, delivering definitive genotyping for clinical management, family planning, and research.
The assay is performed on peripheral whole blood or genomic DNA extracted from buccal samples. Bioinformatics pipelines align reads to GRCh38/hg38 and apply stringent quality filters to achieve 99.9% sensitivity for all variant types in the HBG2 locus.
| Feature | Our HPFH NGS Test | Closest Alternative (Targeted PCR/Sanger) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – full gene coverage | PCR + Sanger sequencing – limited to known hotspots |
| Variant Detection | All SNVs, indels, large rearrangements in HBG2 | Only pre-specified point mutations |
| Turnaround Time | 3 to 4 Weeks | 4–6 Weeks |
| Sensitivity | 99.9% | ~90–95% for common variants |
| Reporting | Full clinical interpretation & genetic counseling note | Technical result only |
Physician Insight & Safety Protocols
“HPFH is typically a benign condition, yet its molecular confirmation is critical for distinguishing it from beta-thalassemia and other hemoglobinopathies that demand active management. This NGS assay provides the resolution needed to guide accurate genetic counseling. Results must always be interpreted alongside hemoglobin electrophoresis and the full clinical picture.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory on Medication & Clinical Management
Important Clinical Guidance
Do not discontinue, adjust, or initiate any prescribed medication or treatment based solely on this genetic result without consultation with your managing physician.
- Exclusion Criteria: Individuals unable to provide informed consent; those currently in hemolytic crisis requiring urgent intervention; recent blood transfusion (< 3 weeks) may compromise DNA quality — consult the laboratory for sample stability guidance.
- Emergency Red Flags: Sudden pallor, unexplained shortness of breath, or severe bone pain warrant immediate emergency evaluation. These symptoms are unrelated to the blood draw procedure and may signal an underlying hematological condition requiring urgent care.
- Pediatric Testing (≤ 18 years): Parental or guardian consent is mandatory. Pre- and post-test genetic counseling is required for all minors. All pediatric data is handled under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Patient FAQ & Clinical Guidance
1. What is the HBG2 HPFH Genetic Test and why is it performed?
This test sequences the entire HBG2 gene to identify variants that cause hereditary persistence of fetal hemoglobin (HPFH). It is performed when hemoglobin electrophoresis shows elevated HbF and clinicians need to differentiate HPFH from beta-thalassemia or delta-beta-thalassemia. Accurate genotyping guides prognosis, family planning, and avoids unnecessary treatments. The analysis is conducted in our ISO 9001:2015 accredited laboratory using validated NGS protocols with full clinical interpretation included in the report.
2. How should I prepare for the blood collection?
No fasting or special diet is required. You should continue all prescribed medications as directed by your physician. If possible, avoid blood transfusions for at least three weeks before sample collection, as donor DNA may interfere with sequencing accuracy. A pre-test genetic counseling session is strongly recommended to document family history and draw a pedigree. Our mobile phlebotomist will collect the sample at your home using temperature-controlled cold-chain transport between 8 AM and 11 PM daily.
3. When will I receive my results and how are they interpreted?
Your comprehensive genomic report will be delivered within 3 to 4 weeks from the date of sample receipt. The report details all detected HBG2 variants, classifies them according to ACMG/AMP guidelines, and provides a clear clinical interpretation. A positive result identifies a variant associated with HPFH — typically a benign finding — that clarifies the cause of elevated HbF. A negative result rules out known HPFH-causing variants in HBG2. Every report is accompanied by telephonic post-test guidance from our clinical genetics team to explain the findings and their implications.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance Framework
All patient data, genetic information, and clinical records are processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety, informed consent, and medical liability follow Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License Number 1143. No genetic data is shared with third parties without explicit patient consent, and all electronic health records are encrypted in transit and at rest.
Clinical & Logistical Metadata
| Test Name | HBG2 Gene Hereditary Persistence of Fetal Hemoglobin (HPFH) Genetic Test – NGS Full Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Days (3 to 4 Weeks) from Sample Receipt |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Extracted Genomic DNA (buccal swab acceptable with prior consultation) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage – Illumina Platform – Bioinformatics Pipeline v3.2 |
| ICD-10-CM Code | D57.4 (Hereditary persistence of fetal hemoglobin [HPFH]), D57.81 (Other hemoglobinopathies) |
| LOINC Code | 36931-8 (HBG2 gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians